Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Jul 2019
Randomized Controlled Trial Multicenter StudyA randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis.
Interleukin 17 is involved in the pathogenesis of psoriasis, a chronic debilitating disease. ⋯ Multiple subcutaneous doses of M1095 showed a favorable safety profile with dose-dependent improvements in psoriasis.